Digital Therapeutics Market / DTx Market is Expected to Reach $21.9 Billion | MarketsandMarkets™
02 févr. 2024 07h30 HE
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Digital Therapeutics Market / DTx market in terms of revenue was estimated to be worth $6.1 billion in 2023 and is poised to reach $21.9 billion by 2028,...
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
29 janv. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Recombinant Proteins Market revenue to hit USD 9 Billion by 2035, says Research Nester
25 janv. 2024 05h30 HE
|
Research Nester
New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The global recombinant proteins market size is slated to expand at ~12.80% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 9...
Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts
23 janv. 2024 08h00 HE
|
ProPhase Labs, Inc.
Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCompany in Late-Stage Discussions with Two Additional Large Global Brands...
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets
08 janv. 2024 08h00 HE
|
Gallant Therapeutics
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
04 janv. 2024 08h00 HE
|
ProPhase Labs, Inc.
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth Garden...
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
03 janv. 2024 08h00 HE
|
Wugen
Wugen Strengthens Executive Leadership Team with the Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
21 déc. 2023 16h00 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of...
Appointment of Chief Business Officer
19 déc. 2023 07h00 HE
|
Avacta Group
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical...
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting
11 déc. 2023 15h00 HE
|
Wugen
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at ASH 2023